Therapeutic remodeling of the tuberculosis granuloma with 1-methyl-D-tryptophan enhances CD8+ T cell-macrophage interactions.
Therapeutic remodeling of the tuberculosis granuloma with 1-methyl-D-tryptophan enhances CD8+ T cell-macrophage interactions. Proc Natl Acad Sci U S A. 2026 08 18; 123(33):e2528104123.
PMID: 42579482
Early immune dysregulation in Mtb/SIV co-infection resists cART treatment at the single-cell level.
Early immune dysregulation in Mtb/SIV co-infection resists cART treatment at the single-cell level. iScience. 2026 Aug 21; 29(8):116944.
PMID: 42565131
Mast cells promote pathology and susceptibility in tuberculosis.
Mast cells promote pathology and susceptibility in tuberculosis. Elife. 2026 Jan 28; 13.
PMID: 41603352
Targeting the lung innate pathways during tuberculosis can improve vaccine-induced protection via Th17 responses in diversity outbred mice.
Targeting the lung innate pathways during tuberculosis can improve vaccine-induced protection via Th17 responses in diversity outbred mice. mBio. 2026 02 11; 17(2):e0323225.
PMID: 41556657
Concurrent TB and HIV therapies control TB reactivation during co-infection but not chronic immune activation.
Concurrent TB and HIV therapies control TB reactivation during co-infection but not chronic immune activation. Nat Commun. 2025 Dec 12; 17(1):499.
PMID: 41387448
Therapeutic remodeling of the tuberculosis granuloma with 1-methyl-D-tryptophan enhances CD8+ T cell-macrophage interactions.
Therapeutic remodeling of the tuberculosis granuloma with 1-methyl-D-tryptophan enhances CD8+ T cell-macrophage interactions. bioRxiv. 2025 Oct 04.
PMID: 41473286
No evidence of MMR induced trained immunity to prevent SARS COV2: results from a multi-centre RCT.
No evidence of MMR induced trained immunity to prevent SARS COV2: results from a multi-centre RCT. Front Immunol. 2025; 16:1588190.
PMID: 41035643
Mast cells promote pathology and susceptibility in tuberculosis.
Mast cells promote pathology and susceptibility in tuberculosis. bioRxiv. 2025 Sep 13.
PMID: 39314389
Development and preclinical evaluation of next-generation ?sigH-based live candidate vaccines.
Development and preclinical evaluation of next-generation ?sigH-based live candidate vaccines. JCI Insight. 2025 10 08; 10(19).
PMID: 40875531
Mincle receptor agonist UM-1098 and TLR4 agonist INI-2002 combination adjuvant enhances Th1 responses and provides protection against Mycobacterium tuberculosis challenge in mice.
Mincle receptor agonist UM-1098 and TLR4 agonist INI-2002 combination adjuvant enhances Th1 responses and provides protection against Mycobacterium tuberculosis challenge in mice. Vaccine X. 2025 Oct; 26.
PMID: 42598270